CYLERT
LOE ApproachingNDAORALTABLET, CHEWABLEPriority Review
Approved
Jan 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYLERT is an oral small-molecule tablet (including chewable formulation) approved in 1976 by Abbott. The mechanism of action and specific indications are not documented in available data, limiting characterization of its therapeutic use.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team likely operates in maintenance mode with minimal commercial expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and a product approaching loss of exclusivity, CYLERT offers limited career growth and mobility within Abbott's portfolio. Professionals assigned to this product should expect focus on cost management, compliance, and transition planning rather than expansion or innovation.
Brand ManagerField Sales Representative
Worked on CYLERT at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.